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Background
The naturally resistance of HIV-2 to non-nucleoside
reverse transcriptase inhibitors and T-20, as well as its
reduced susceptibility to some protease inhibitors makes
the nucleoside reverse transcriptase inhibitors (NRTI) cru-
cial in HIV-2 therapy. Hence, early detection of resistance
mutations to NRTI is important to explain treatment fail-
ures and to guide therapy.
Materials and methods
HIV-2 OLA was developed for the Q151M and M184V
mutations using a set of 3 oligonucleotide probes for each
mutation. 90 HIV-2 samples from Guinea Bissau, the
Gambia and Sweden were amplified, sequenced and eval-
uated in OLA.
Results
OLA sensitivity was 100% for Q151M and 98% for
M184V. Concordance between sequencing and OLA was
99% and 97% for the Q151M and M184V mutations
respectively.
Conclusion
OLA was successfully developed for major HIV-2 muta-
tions. Its ease-of-use, economical nature and high con-
cordance with sequencing makes it more appropriate for
use in resource-poor settings.
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